|1.||Komori, Takahide: 3 articles (01/2011 - 01/2007)|
|2.||Butler, Charles E: 3 articles (04/2007 - 08/2004)|
|3.||Sclafani, A P: 3 articles (11/2001 - 04/2000)|
|4.||Jacono, A A: 3 articles (11/2001 - 04/2000)|
|5.||Deeken, Corey R: 2 articles (08/2015 - 05/2011)|
|6.||Frisella, Margaret M: 2 articles (08/2015 - 05/2011)|
|7.||Matthews, Brent D: 2 articles (08/2015 - 05/2011)|
|8.||Bochicchio, Grant V: 2 articles (10/2013 - 01/2008)|
|9.||Potochny, John: 2 articles (09/2013 - 10/2012)|
|10.||Brooke, Sebastian: 2 articles (09/2013 - 10/2012)|
01/01/2008 - "Serial Gore-Tex excision to facilitate primary fascial closure with AlloDerm sublay is an effective treatment for massive, incisional hernias with loss of abdominal domain and avoids the risks associated with long-term prosthetic fascial closures."
01/01/2014 - "Use of AlloDerm greatly enhanced the maneuverability during laparoscopic hernia repair due to its pliability and strength and eliminated the need to cover the prosthetic with peritoneum. "
10/01/2008 - "The purpose of this study is to review a single institution's experience with the use of human acellular dermal matrix (HADM [AlloDerm]) for repair of hernias. "
11/01/2006 - "The aim of the current study was to determine what factors predicted fascial wall failure as determined by the presence of hernia on follow-up exam after AlloDerm placement. "
01/01/2014 - "AlloDerm is a reasonable choice for groin hernia repairs when such factors are present. "
01/01/2006 - "The purpose of this study was to examine the rate of fistula closure using conventional surgical techniques (Group 1) versus a newer technique (Group 2) employing the use of acellular dermal matrix (AlloDerm). "
02/01/2010 - "We present a case of a catastrophic bronchopleural fistula that was successfully closed using an Alloderm patch (LifeCell Corp, Branchburg, NJ) in the acute setting."
09/01/2009 - "We describe the use of Alloderm (LifeCell Corp, Branchburg, NJ), a biologic scaffold, to repair a large fistula between the proximal left mainstem bronchus and the esophagus."
01/01/2006 - "The use of AlloDerm during palatal fistula repair is safe, effective over time, and has the potential to reduce palatal fistula recurrence rates."
01/01/2006 - "Fistula closure was obtained in 100% of the patients in Group 2. There were no complications noted other that the failure of the 2 patients in Group 1. The use of AlloDerm in palatal fistula repair has reduced our failure rate from 16.7% to 0%. "
02/01/2004 - "Its biologic nature provides AlloDerm with an improved capacity to reintegrate with surrounding tissues and less inclination toward infection, erosion, extrusion, and rejection compared with synthetic tissue replacement materials. "
12/01/2009 - "The purpose of this study was to review the author's experience with AlloDerm-assisted prosthetic breast surgery and determine the tolerance in the setting of infection and irradiation. "
10/01/2015 - "Patients receiving AlloDerm were half as likely to have major infections compared with patients receiving FlexHD (OR, 0.50; 95 percent CI, 0.16 to 1.00; p < 0.05). "
09/01/2015 - "Contour fenestrated AlloDerm reduces infections compared with aseptic AlloDerm, but infection rates are similar to those of sterile, ready-to-use AlloDerm and total submuscular coverage."
04/01/2011 - "Non-cross-linked porcine biologics were less likely to be explanted (16.7%) but had higher recurrence (29.4%) compared to cross-linked porcine biologics and a higher infection rate (54.2%) compared to AlloDerm. "
05/01/2013 - "Seroma was the most prevalent complication; the seroma rate for AlloDerm (15.7 percent) was significantly greater than that for SurgiMend (8.3 percent). "
06/01/2012 - "Total complications were significantly higher with AlloDerm (21.4 percent versus 6.3 percent; p = 0.0003) and were driven by a significantly higher seroma rate (12.7 percent versus 1.4 percent; p = 0.0003). "
03/01/2014 - "RTU AlloDerm was associated with higher rates of seroma and cellulitis compared with FD AlloDerm (22.0% vs 18.8%, P = 0.599 and 21.0% vs 12.5%, P = 0.129, respectively). "
09/01/2013 - "In this study, we aimed to evaluate clinically significant seroma (CSS) formation-defined by the need for a drainage procedure-to determine if there was a difference in incidence between product types: AlloDerm (AL), DermaMatrix (DM), and FlexHD (FHD). "
06/01/2012 - "Animals for each implant developed seromas: AlloDerm 40%, Permacol 33%, and CollaMend 83%. "
09/01/2011 - "Exploration of scar or lamina propria through the fenestration allowed for the creation of a pocket for Alloderm implantation within the intermediate layer of the lamina propria. "
08/01/2010 - "Alloderm doesn't undergo the same proliferative process as keloidal scar dermis. "
05/01/2010 - "The scar thickness of non-AlloDerm applied areas was 2.5+/-0.9 mm and AlloDerm applied areas was 1.8+/-0.7 mm (p = 0.396). "
01/01/2005 - "Surgical correction included subperiosteal midface-lift and middle lamellae scar lysis, in addition to thick AlloDerm graft placement to the lower eyelid. "
01/01/2005 - "Retrospective analysis of patients undergoing lower eyelid reconstruction, which encompassed subperiosteal midface lifting, middle lamellae scar lysis, and placement of lower eyelid thick AlloDerm graft. "
|8.||Collagen Type IV (Type IV Collagen)
|10.||Fibrin Tissue Adhesive (Fibrin Sealant)
|4.||Mammaplasty (Breast Reconstruction)
|5.||Homologous Transplantation (Allograft)